DK3773537T3 - Stat3-hæmmere - Google Patents

Stat3-hæmmere Download PDF

Info

Publication number
DK3773537T3
DK3773537T3 DK19788688.0T DK19788688T DK3773537T3 DK 3773537 T3 DK3773537 T3 DK 3773537T3 DK 19788688 T DK19788688 T DK 19788688T DK 3773537 T3 DK3773537 T3 DK 3773537T3
Authority
DK
Denmark
Prior art keywords
hæmmere
stat3
Prior art date
Application number
DK19788688.0T
Other languages
English (en)
Inventor
Sofia De Achaval Wied
William E Bauta
William R Cantrell Jr
David John Tweardy
Original Assignee
Tvardi Therapeutics Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tvardi Therapeutics Inc, Baylor College Medicine filed Critical Tvardi Therapeutics Inc
Application granted granted Critical
Publication of DK3773537T3 publication Critical patent/DK3773537T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK19788688.0T 2018-04-19 2019-04-18 Stat3-hæmmere DK3773537T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659872P 2018-04-19 2018-04-19
US201962793491P 2019-01-17 2019-01-17
PCT/US2019/028135 WO2019204614A1 (en) 2018-04-19 2019-04-18 Stat3 inhibitors

Publications (1)

Publication Number Publication Date
DK3773537T3 true DK3773537T3 (en) 2022-04-25

Family

ID=68240338

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19788688.0T DK3773537T3 (en) 2018-04-19 2019-04-18 Stat3-hæmmere

Country Status (18)

Country Link
US (2) US11826315B2 (da)
EP (2) EP3773537B1 (da)
JP (1) JP7411315B2 (da)
KR (1) KR102792113B1 (da)
CN (1) CN112367984B (da)
AU (1) AU2019255755B2 (da)
BR (1) BR112020021329A2 (da)
DK (1) DK3773537T3 (da)
ES (1) ES2911428T3 (da)
HU (1) HUE059318T2 (da)
IL (1) IL278112B2 (da)
MX (1) MX2020011065A (da)
MY (1) MY207195A (da)
PH (1) PH12020551728A1 (da)
PL (1) PL3773537T3 (da)
PT (1) PT3773537T (da)
SG (1) SG11202010347XA (da)
WO (1) WO2019204614A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11826315B2 (en) * 2018-04-19 2023-11-28 Tvardi Therapeutics STAT3 inhibitors
CN114761405A (zh) * 2019-11-29 2022-07-15 南京明德新药研发有限公司 抗hbv的1,7-萘啶类化合物
CA3163745A1 (en) * 2019-12-03 2021-06-10 Baylor College Of Medicine Therapeutic compounds for methods of use in insulin resistance
CA3159181A1 (en) 2020-01-24 2021-07-29 Imran ALIBHAI Therapeutic compounds, formulations, and uses thereof
WO2022022524A1 (en) * 2020-07-27 2022-02-03 Huazhong University Of Science & Technology Prevention and/or treatment of a disease associated with stat3
TW202341973A (zh) * 2022-03-01 2023-11-01 美商特梵迪治療股份有限公司 治療性化合物、調配物、及其用途
WO2023168420A1 (en) * 2022-03-04 2023-09-07 Tvardi Therapeutics, Inc. Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer
WO2023244946A1 (en) * 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. Prodrugs of stat3 inhibitors
TW202412749A (zh) * 2022-07-21 2024-04-01 美商特梵迪治療股份有限公司 治療性化合物、調配物、及其用途
WO2024129619A1 (en) * 2022-12-12 2024-06-20 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of non-viral liver cancer
WO2025184497A1 (en) * 2024-02-29 2025-09-04 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4279909A (en) 1980-02-13 1981-07-21 Fujisawa Pharmaceutical Co., Ltd. Antiallergic method
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
JP2004501147A (ja) 2000-06-20 2004-01-15 アセロジエニクス・インコーポレイテツド 1,3−ビス−(置換フェニル)−2−プロペン−1−オン類およびvcam−1媒介障害を治療するためのそれらの使用
US20040048795A1 (en) 2002-02-26 2004-03-11 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
US20050287664A1 (en) 2004-05-27 2005-12-29 Ming-Ji Fann Cellular proliferation control factors
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
EP1915162A4 (en) 2005-07-27 2009-08-26 Agency Science Tech & Res Modulators
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
EP1981489B1 (en) 2006-01-13 2013-05-01 The Feinstein Institute for Medical Research Inhibition of inflammatory cytokine production with tanshinones
US7960434B2 (en) 2006-05-19 2011-06-14 University Of South Florida Small molecule inhibitors of STAT3 with anti-tumor activity
US20090264353A1 (en) 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009038784A1 (en) 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
EP2299999B1 (en) * 2008-06-04 2017-08-16 Baylor College Of Medicine Stat3 inhibitors
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2010080581A2 (en) 2008-12-19 2010-07-15 The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
US9891213B2 (en) 2009-01-12 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Granulocyte-based methods for detecting and monitoring immune system disorders
JP2013512248A (ja) 2009-11-24 2013-04-11 ジ・オハイオ・ステート・ユニバーシティ 転写因子阻害剤および関連する組成物、製剤および方法
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US20140371188A1 (en) 2011-11-23 2014-12-18 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
CN102766103B (zh) * 2012-07-24 2014-12-10 齐鲁制药有限公司 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
CA2919517C (en) * 2013-07-18 2022-04-19 David J. Tweardy Methods and compositions for treatment of fibrosis
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
AU2014290367B2 (en) 2013-07-18 2019-10-03 Baylor College Of Medicine Methods and compositions for prevention of allergic reaction
WO2017083719A1 (en) 2015-11-13 2017-05-18 William Marsh Rice University Transition metal free methods of synthesis of biaryl compounds
US11826315B2 (en) * 2018-04-19 2023-11-28 Tvardi Therapeutics STAT3 inhibitors
US11026905B2 (en) * 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
CA3159181A1 (en) * 2020-01-24 2021-07-29 Imran ALIBHAI Therapeutic compounds, formulations, and uses thereof

Also Published As

Publication number Publication date
CN112367984A (zh) 2021-02-12
AU2019255755B2 (en) 2024-07-25
EP3773537B1 (en) 2022-03-23
EP3773537A1 (en) 2021-02-17
SG11202010347XA (en) 2020-11-27
US20210114980A1 (en) 2021-04-22
CN112367984B (zh) 2024-05-10
MX2020011065A (es) 2021-01-20
CA3097403A1 (en) 2019-10-24
IL278112B1 (en) 2023-03-01
KR20210011925A (ko) 2021-02-02
EP4070790A1 (en) 2022-10-12
IL278112A (da) 2020-12-31
US20240058284A1 (en) 2024-02-22
JP7411315B2 (ja) 2024-01-11
JP2021521243A (ja) 2021-08-26
KR102792113B1 (ko) 2025-04-04
PH12020551728A1 (en) 2021-06-14
PT3773537T (pt) 2022-04-19
US11826315B2 (en) 2023-11-28
PL3773537T3 (pl) 2022-05-23
HUE059318T2 (hu) 2022-11-28
AU2019255755A1 (en) 2020-12-03
MY207195A (en) 2025-02-05
WO2019204614A1 (en) 2019-10-24
ES2911428T3 (es) 2022-05-19
IL278112B2 (en) 2023-07-01
EP3773537A4 (en) 2021-05-26
BR112020021329A2 (pt) 2021-04-27

Similar Documents

Publication Publication Date Title
DK3793565T3 (en) Mcl-1-inhibitorer
DK3467457T3 (en) Vibrationssensor
DK3759096T3 (en) Cd73-inhibitorer
CA185383S (en) Casque
CA185382S (en) Casque
CA185384S (en) Casque
CA185385S (en) Casque
DK3872428T3 (en) Indvendigt luftstyringssystem
DK3773537T3 (en) Stat3-hæmmere
DK3554057T3 (en) Audioheadsetsystem
DK3768830T3 (en) Cancerterapi
CA184994S (en) Uroflowmeter
DK3613739T3 (en) Integrin-antagonister
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184991S (en) Uroflowmeter
GB201802611D0 (en) Teleporter
DK3633783T3 (en) Universal-powerbank
EP3841303C0 (de) Mikrogebläse
DK3801538T3 (en) Tlr7-agonister
DK3768906T3 (en) Træmodul
DK3650069T3 (en) Trakeostomiventil
DK3578923T3 (en) Navigationssystem
GB201802378D0 (en) Roadplate
GB201801914D0 (en) Mouth-guard
DK3674425T3 (en) Stålwire